Opendata, web and dolomites

STRICT SIGNED

SN: The first blood biomarker to accurately STratify mortality Risk In patients with Cardiac arrhyTmia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 STRICT project word cloud

Explore the words cloud of the STRICT project. It provides you a very rough idea of what is the project "STRICT" about.

sudden    lvef    blood    implantable    regime    67    difficult    accurate    biomedical    health    secretoneurin    ecg    reducing    ejection    arrhythmias    exams    3b    status    cardinor    never    expertise    burden    maturation    shown    coming    defibrillator    eligible    data    diagnosis    vitro    surgery    quality    boost    ask    ventricle    device    patients    global    survival    risk    detect    house    positioning    unknowingly    sme    decision    patented    saving    ventricular    recruit    innovation    killer    cardiovascular    linked    trl8    51    least    scd    disease    normal    death    associate    35    competitive    lives    icds    20k    worldwide    arrythmia    echocardiogram    company    diagnostic    advantage    cardioverter    activated    caused    cvd    assurance    cardiologists    stratify    correlation    cardiac    biomarkers    alone    25    ivd    skills    icd    patient    left    market    victims    levels    acquiring    globally    pinpoint    biomarker    physical    lt    mortality    sn    overtreatment   

Project "STRICT" data sheet

The following table provides information about the project.

Coordinator
CARDINOR AS 

Organization address
address: GAUSTADALLEEN 21
city: OSLO
postcode: 349
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Total cost 119˙805 €
 EC max contribution 119˙805 € (100%)
 Programme 1. H2020-EU.2.3.2.2. (Enhancing the innovation capacity of SMEs)
 Code Call H2020-INNOSUP-2019-02
 Funding Scheme CSA
 Starting year 2019
 Duration (year-month-day) from 2019-12-15   to  2020-12-14

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CARDINOR AS NO (OSLO) coordinator 119˙805.00

Map

 Project objective

Cardiovascular disease (CVD) is the no. 1 killer worldwide. 25% of all CVD mortality is caused by ventricular arrhythmias that lead to sudden cardiac death (SCD). The diagnosis of arrhythmias is difficult but crucial for accurate decision-making and patient survival. To assess the patient’s status, cardiologists currently ask: physical exams, some cardiac biomarkers data, an ECG (which may detect an arrythmia) and an echocardiogram to measure the blood ejection from the left ventricle (LVEF), since there is a correlation between LVEF and risk of ventricular arrhythmias. If LVEF is < 35%, the patient is eligible for implantable cardioverter-defibrillator (ICD) surgery, which costs at least 20K€. Still, around 51 % of victims of SCD have normal LVEF. In addition, 67% of all implemented ICDs are never activated because those patients were (unknowingly) at low-risk for arrhythmias, which represents a 1.3B€ overtreatment cost / year in the EU alone. CardiNor is bringing to market a new in vitro diagnostic (IVD) test to measure blood levels of Secretoneurin (SN), a globally patented biomarker and the only one shown to be specifically linked to ventricular arrhythmias. With SN data, cardiologists will be able to stratify patients according to their risk as well as to pinpoint high-risk patients not identified by the current diagnostic regime, thus reducing health burden costs and saving lives. CardiNor needs the SME Innovation Associate Programme to boost R&D activities within test maturation and effectively take it to TRL8. Currently, we do not have in-house expertise in biomedical device development or quality assurance. Therefore, we are looking to recruit an Innovation Associate. Acquiring these skills is important for CardiNor to maintain competitive advantage over coming years, positioning our company to high growth in the global CVD biomarkers market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STRICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STRICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.2.2.)

MontEENegro (2020)

Enhancing innovation management capacities of SMEs in Montenegro

Read More  

PROSME INN (2020)

PROSME INN- Improving RO3 SMEs management of innovation

Read More  

E3Canarias 2020-2021 (2020)

Enhancing the innovation management capacity of SMEs with the Enterprise Europe Network Canarias 2020-2021

Read More